More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Cyclosporin A [59865-13-3]
Chemical Structure
Chemical Structure
Chemical Structure

Cyclosporin A [59865-13-3]

Research Use Only
AG-CN2-0079
AdipoGen Life Sciences
CAS Number59865-13-3
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight1202.6
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Cyclosporin A [59865-13-3]
  • Delivery Days Customer
    10
  • CAS Number
    59865-13-3
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Danger
  • Molecular Formula
    C62H111N11O12
  • Molecular Weight
    1202.6
  • Scientific Description
    Chemical. CAS: 59865-13-3. Formula: C62H111N11O12. MW: 1202.6. Isolated from Tolypocladium inflatum. Potent immunosuppressant (same as FK-506 (Prod. No. AG-CN2-0047) and rapamycin (Prod. No. AG-CN2-0025)). Forms a complex with cyclophilin. Inhibits the activity of the calcium/calmodulin-dependent protein phosphatase 2B (PP2B; calcineurin). Prevents the dephosphorylation of nuclear factor of activated T cells (NFAT) transcription factor, leading to disruption of T cell activation. Suppresses proliferation of cytotoxic T cells and inhibits the production of T cell-derived mediators such as interleukin-2 (IL-2). Prevents rejection of transplanted organs. Anti-inflammatory compound in the treatment of several inflammatory skin diseases (e.g. atopic dermatitis) and with potential anti-rheumatic activity (rheumatoid arthritis). Antibacterial. Antifungal. Antiparasitic. Apoptosis inhibitor. Inhibits the mitochondrial permeability transition pore (MPTP) from opening, thus inhibiting cytochrome c release. NF-kappaB suppressor by induction of unfolded protein response (UPR). Anti-cancer compound. Apoptosis and autophagy inducer. Inhibits nitric oxide synthesis induced by interleukin-1alpha, lipopolysaccharides and TNF-alpha. Potently induces highly cardiogenic progenitors from embryonic stem (ES) cells. - Potent immunosuppressant (same as FK-506 (Prod. No. AG-CN2-0047) and rapamycin (Prod. No. AG-CN2-0025)). Forms a complex with cyclophilin. Inhibits the activity of the calcium/calmodulin-dependent protein phosphatase 2B (PP2B; calcineurin). Prevents the dephosphorylation of nuclear factor of activated T cells (NFAT) transcription factor, leading to disruption of T cell activation. Suppresses proliferation of cytotoxic T cells and inhibits the production of T cell-derived mediators such as interleukin-2 (IL-2). Prevents rejection of transplanted organs. Anti-inflammatory compound in the treatment of several inflammatory skin diseases (e.g. atopic dermatitis) and with potential anti-rheumatic activity (rheumatoid arthritis). Antibacterial. Antifungal. Antiparasitic. Apoptosis inhibitor. Inhibits the mitochondrial permeability transition pore (MPTP) from opening, thus inhibiting cytochrome c release. NF-kappaB suppressor by induction of unfolded protein response (UPR). Anti-cancer compound. Apoptosis and autophagy inducer. Inhibits nitric oxide synthesis induced by interleukin-1alpha, lipopolysaccharides and TNF-alpha. Potently induces highly cardiogenic progenitors from embryonic stem (ES) cells.
  • SMILES
    [H][C@@]1([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O)C(C)C
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A: D.A. Fruman, et al.; PNAS 89, 3686 (1992)
  • Cyclosporin A, FK506 and rapamycin: more than just immunosuppression: J. Kunz & M.N. Hall; TIBS 18, 334 (1993)
  • Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology: B.E. Bierer, et al.; Curr. Opin. Immunol. 5, 763 (1993)
  • Immunological actions of cyclosporin A in rheumatoid arthritis: D. Yocum; Br. J. Rheumatol. 32, 38 (1993)
  • The antimicrobial activities of cyclosporine, FK506, and rapamycin: H.P. High; Tansplantation 57, 1689 (1994) (Review)
  • Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2: A.R. Gottschalk, et al.; PNAS 91, 7350 (1994)
  • Inhibition of the mitochondrial permeability transition pore by cyclosporin A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases. K.M. Broekemeier & D.R. Pfeiffer; Biochemistry 34, 16440 (1995)
  • Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide-treated J774 macrophages: Y. Hattori & N. Naranishi; Cell Immunol. 165, 7 (1995)
  • Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection: A.W. Thomson & C.A. Bonham; Adv. Exp. Med. Biol. 374, 211 (1995) (Review)
  • FK506 in the treatment of inflammatory skin disease: promises and perspectives: G. Michel, et al.; Immunol. Today 17, 106 (1996) (Review)